Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Gains from Investment Securities (2022 - 2025)

Historic Gains from Investment Securities for 60 Degrees Pharmaceuticals (SXTP) over the last 4 years, with Q3 2025 value amounting to $226682.0.

  • 60 Degrees Pharmaceuticals' Gains from Investment Securities changed N/A to $226682.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $260199.0, marking a year-over-year decrease of 6906.79%. This contributed to the annual value of $2000.0 for FY2024, which is 9921.88% down from last year.
  • Latest data reveals that 60 Degrees Pharmaceuticals reported Gains from Investment Securities of $226682.0 as of Q3 2025.
  • In the past 5 years, 60 Degrees Pharmaceuticals' Gains from Investment Securities ranged from a high of $1.7 million in Q2 2024 and a low of -$865743.0 during Q3 2023
  • Its 4-year average for Gains from Investment Securities is $98808.4, with a median of $8259.0 in 2022.
  • As far as peak fluctuations go, 60 Degrees Pharmaceuticals' Gains from Investment Securities tumbled by 89600.4% in 2023, and later surged by 2177833.84% in 2024.
  • Quarter analysis of 4 years shows 60 Degrees Pharmaceuticals' Gains from Investment Securities stood at $1001.0 in 2022, then crashed by 2137.16% to -$20392.0 in 2023, then surged by 176.09% to $15517.0 in 2024, then soared by 1360.86% to $226682.0 in 2025.
  • Its Gains from Investment Securities stands at $226682.0 for Q3 2025, versus $18000.0 for Q1 2025 and $15517.0 for Q4 2024.